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CASE REPORT
Multiple fixed drug eruption to
minocycline at sites of healed burn
and zoster: An interesting case of locus
minoris resistentiae
Renata Dalla Costa, BS,a,b Connie Yihan Yang, BA,a,c Molly Stout, MD,d Daniela Kroshinsky, MD, MPH,a and
Arianne Shadi Kourosh, MD, MPHa
Boston and Worcester, Massachusetts
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INTRODUCTION
Fixed drug eruptions (FDEs) are a subset of
cutaneous drug reactions characterized by the devel-
opment of well-demarcated nummular dusky
erythematous plaques when exposed to an offending
agent, which recur at the same site on re-exposure.
With removal of the trigger, lesions disappear, often
leaving residual hyperpigmentation.
The gold standard for FDE diagnosis is reproduc-
ible provocation of the lesions with the same
offending agent.1 Of the various agents associated
with FDE, antimicrobial agents (sulfonamides,
trimethoprim, and tetracyclines), analgesics (nonste-
roidal anti-inflammatory drugs), sedatives (barbitu-
rates), and anticonvulsants are among the most
commonly reported.2
FDEs induced byminocycline have been identified
since the 1970s.3 Although the exact incidence of
tetracycline-associated FDEs is difficult to assess,
multiple studies list the tetracyclines among the most
common triggers,4 and some identify themas themost
common in the case of genital FDEs.5 However, the
pathophysiology of plaque recurrence at the same
location is not fully understood. In some cases, these
recurrences have been seen at former sites of trauma.
We report a case of minocycline-induced FDE local-
ized to sites of a previous burn and zoster.
CASE
A 34-year-old woman was prescribed minocy-
cline, 100 mg twice a day, for acneiform lesions.
Within 4 days of starting the medication, a well-
demarcated, tender, nummular dusky erythematous
plaque developed on the right upper chest (Fig 1),
the site of a healed curling iron burn that she
sustained 2 months prior. The patient denied any
other medication use or trauma to the affected site
and noted that the lesion regressed on discontinua-
tion of minocycline. Before this incident, she had
taken minocycline with no side effects. The patient is
a physician and suspected that she had an FDE to
minocycline. Thus, 2 months later, after the site had
fully healed, she rechallenged herself with this
medication. Within 2 days of minocycline use, the
plaque on the right upper chest recurred (Fig 2)
along with an additional plaque of similar appear-
ance on the right lateral chest situated under her
brassiere strap. The minocycline was discontinued,
and the lesions healed, leaving a hyperpigmented
patch at the site of the right lateral chest (Fig 3). Upon
further inquiry, the patient reported that she had an
episode of shingles 15 years ago at the location of the
second plaque. She declined biopsy because of
concerns for scarring. Instead, she chose to rechal-
lenge herself a final timewithminocycline to confirm
that the medication was the cause of these lesions.
Abbreviations used:
FDE: fixed drug eruption
LMR: locus minoris resistentiae
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One month after her previous challenge, she took 1
dose of minocycline and noted that both lesions
reappeared within 24 hours.
DISCUSSION
The term fixed drug eruption denotes one of the
diagnostic characteristics of this condition: the
recurrence of lesions at the same site. Much remains
to be understood regarding why these plaques
recur at the same locations, although in some cases,
it is thought to be related to prior insult at the
affected site.
As in the mythologic tale of the Greek hero
Achilles, who was killed by an arrow striking his
heel, which was the only vulnerable site on his body,
the concept of locus minoris resistentiae (LMR)
describes an area of the body more vulnerable than
others, possibly as a result of a prior insult.6
In our case, this FDE caused by minocycline
occurred at 2 sites of prior injury: a site of thermal
injury and a site of prior herpes zoster infection that
had also been subject to recurrent friction. These
injured sites have a lower threshold for FDE lesion
development, illustrating the concept of LMR. Cases
of LMR similar to that of the first site of thermal injury
have been documented in other patients, although
these cases were caused by other forms of electro-
magnetic radiation, such as sun exposure.7
The eruption at the patient’s second site of injury
showed a phenomenon similar to LMR but more
specific to dermatology: Wolf’s isotopic response.
This term describes the occurrence of a new
dermatosis at the exact site of another previously
unrelated and healed skin lesion (classically herpes
zoster).8 This case shows the simultaneous occur-
rence of LMR and Wolf’s isotopic response in the
same FDE as a result of 2 different types of prior
insult.
Although much remains to be learned regarding
the pathophysiology of these phenomena, it was
theorized that resident T cells recruited from the
bloodstream after an insult (eg, infection or
trauma) may remain in the affected area for long
periods after resolution of the initial insult. In
FDEs, these cells may cross-react with a triggering
antigen and become reactivated upon re-exposure
to the agent.9
Although FDEs at sites of prior trauma have
been reported,10 this is the first case, to our
knowledge, of minocycline triggering the
Fig 1. Dusky erythematous plaque after 4 days of
minocycline use.
Fig 2. Well-demarcated dusky erythematous plaque after
minocycline rechallenge.
Fig 3. Residual hyperpigmentation on the right lateral
chest.
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phenomenon of LMR in the form of an FDE at a
burn site, and then on re-exposure to the drug,
simultaneous development of a Wolf’s isotopic
response at a second site of chronic friction and
resolved varicella-zoster virus infection.
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